Numerous psychotropic drugs bind to Sigma1R, making Sigma1R a potential druggable target for controlling seizures and non-seizure CNS comorbidities related to both seizure activity over time and the underlying pathology of Dravet syndrome and other DEEs [50,52,68]. This evidence concerns the gene SIGMAR1 and encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.